DiaMedica Therapeutics Inc (DMAC) reports a robust cash position and significant clinical advancements, despite facing enrollment challenges in its ReMEDy2 trial. MINNEAPOLIS, March 17 ...

DiaMedica Therapeutics progresses DM199 for ischemic stroke and preeclampsia, aiming to expand treatment windows. Read why ...

DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199 DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has entered into an agreement with accredited investors that have ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2024 Earnings Call Transcript March 18, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2024 ...

The latest price target for DiaMedica Therapeutics (NASDAQ:DMAC) was reported by HC Wainwright & Co. on March 19, 2025. The analyst firm set a price target for $10.00 expecting DMAC to rise to ...

DIAMEDICA THERAPEUTICS ($DMAC) is expected to release its quarterly earnings data on Monday, March 17th after market close, per Finnhub. Analysts are expecting ...

North Carolina’s Drought Management Advisory Council (DMAC) says severe drought is impacting portions of: “This current dry spell in North Carolina began with a very dry October and warm ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2024 Conference Call. An audio recording of the webcast will be available shortly after the call today on ...